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Background: Endovenous ablation techniques and ultrasound-guided foam sclerotherapy (UGFS) have
largely replaced open surgery for treatment of great saphenous varicose veins. This was a randomized
trial to compare the effect of surgery, endovenous laser ablation (EVLA) (with phlebectomies) and UGFS
on quality of life and the occlusion rate of the great saphenous vein (GSV) 12months after surgery.
Methods: Patients with symptomatic, uncomplicated varicose veins (CEAP class C2–C4) were examined
at baseline, 1month and 1 year. Before discharge and at 1week, patients reported a pain score on a
visual analogue scale. Preoperative and 1-year assessments included duplex ultrasound imaging and the
Aberdeen Varicose Vein Severity Score (AVVSS).
Results: The study included 214 patients: 65 had surgery, 73 had EVLA and 76 had UGFS. At 1 year,
the GSV was occluded or absent in 59 (97 per cent) of 61 patients after surgery, 71 (97 per cent) of
73 after EVLA and 37 (51 per cent) of 72 after UGFS (P<0⋅001). The AVVSS improved significantly
in comparison with preoperative values in all groups, with no significant differences between them.
Perioperative pain was significantly reduced and sick leave shorter after UGFS (mean 1day) than after
EVLA (8days) and surgery (12 days).
Conclusion: In comparison with open surgery and EVLA, UGFS resulted in equivalent improvement in
quality of life but significantly higher residual GSV reflux at 12-month follow-up.
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Introduction
Invasive treatment of superficial varicose veins and venous
reflux improves quality of life compared with conservative
treatment with compression stockings1. Conventional
treatment of the incompetent great saphenous vein (GSV)
has been surgical high ligation and stripping, combined
with local phlebectomies. During the past decade, min-
imally invasive techniques, including ultrasound-guided
foam sclerotherapy (UGFS) and endovenous laser abla-
tion (EVLA) have gained popularity in the treatment of
varicose veins, and have largely replaced surgery. These
new techniques are less invasive than the conventional
surgery, and are associated with shorter postoperative
recovery, owing to less pain, as well as fewer complications
such as haematoma, groin infection and nerve damage2–5.
In recent studies comparing open surgery with UGFS
and EVLA5–7, residual reflux was significantly more
common after foam sclerotherapy compared with the
other two treatments after 1 year. A recently published
Cochrane systematic review8 comparing endovenous
ablation (radiofrequency or laser) and UGFS versus open
surgery suggested that EVLA and UGFS are at least as
effective as surgery for great saphenous varicose veins
in terms of patient satisfaction, but not in terms of
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anatomical success. Owing to variation in both the quality
of the studies and reporting of the results, the quality of
the evidence was graded only moderate.
The aim of the present randomized trial was to com-
pare the efficacy of surgery, EVLA and UGFS in patients
with primary symptomatic, uncomplicated great saphenous
varicose veins (Clinical Etiologic Anatomic Pathophysio-
logic (CEAP) clinical grade C2–C4).
Methods
Consecutive patients with varicose veins were screened at
two participating university hospitals in Finland between
November 2007 and May 2010. Patients who fulfilled
the inclusion criteria and were willing to participate were
enrolled in a prospective randomized trial. The study was
approved by the Ethics Committee of Helsinki Univer-
sity Central Hospital and Tampere University Hospital.
All patients provided written informed consent before par-
ticipating in the study, according to the principles of the
Declaration of Helsinki.
The inclusion criteria were: unilateral symptomatic,
uncomplicated varicose veins (CEAP clinical classification
C2–C4), duplex ultrasound-verified reflux in the GSV,
mean diameter of the GSV in the thigh 5–10mm, and
age 20–70 years. Duplex ultrasound imaging was done in
standing position, and reflux was measured after pneumatic
compression of the calf. Incompetence was defined as a
reflux of more than 0⋅5 s.
Exclusion criteria were: peripheral arterial disease, lym-
phoedema, BMI exceeding 40 kg/m2, pregnancy, allergy to
the sclerosant or lidocaine, severe general illness, malig-
nancy, previous deep vein thrombosis and coagulation
disorder.
Randomization
The patients were randomized in outpatients to receive
surgery, EVLA or UGFS. This was done using block
randomization with sealed envelopes.
Procedures
Both the surgical and EVLA procedures were performed
in the day surgery unit.
In the surgical procedure, the saphenofemoral junction
(SFJ) was exposed in the groin and side branches were
ligated back to the femoral vein. Retrograde invagina-
tion stripping of the GSV was done, usually down to
below the knee. Tumescent solution (450ml Ringer’s
solution with 50ml 1 per cent lidocaine with adrenaline
(epinephrine)) was injected into the tunnel of the stripped
GSV. After stripping, hook phlebectomies were done
through tiny incisions, using tumescent solution to mini-
mize haematoma formation. The wound in the groin was
closed with subcuticular sutures. Phlebectomy wounds
were closed with surgical tape. Most patients had general
anaesthesia. After the procedure, the leg was wrapped in
bandages and covered with a class 2 graduated compression
stocking. After 48 h, patients removed their bandages and
then used the stocking alone during the day for up to
2weeks. A prescription for paracetamol with, or without
codeine, or ibuprofen was given on discharge with the
instruction that the medication be used when necessary.
EVLA procedures were done under tumescent local
anaesthesia (same solution as above) injected around the
GSV under ultrasound guidance. A light sedative was
administered before (diazepam) and during (alfentanil,
propofol) the procedure. The laser ablation was carried out
under duplex guidance. At the beginning of the study, a
980-nm diode laser (Ceralas® D 980; Biolitec, Bonn, Ger-
many) was used, but during the study this was replaced with
a 1470-nm radial laser (ELVes®; Biolitec). A pulsed mode,
with a 1⋅5-s impulse and 12W of energy, was used rou-
tinely, with the aim of applying 70 J/cm GSV. The EVLA
catheter tip was positioned 1⋅5–2 cm below the SFJ using
ultrasound guidance. After the laser procedure, phlebec-
tomies were done, as in the surgical procedure. No skin
sutures were used. Thereafter, the protocol was the same
as that after the surgical procedure.
UGFS was undertaken in outpatients by a vascu-
lar surgeon with an assisting nurse. Patients were
examined by duplex ultrasound imaging before the
treatment with the patient standing, and the cause of
reflux was confirmed. During the treatment the patient
remained supine. The GSV was cannulated under ultra-
sound guidance, usually at proximal thigh level and
immediately below the knee. The sclerosant foam was
prepared with a double-syringe technique with a scle-
rosant to air ratio of 1 : 2. The sclerosants used were
polidocanol 1 per cent (Aetoxysclerol®; Kreussler, Wies-
baden, Germany) and sodium tetradecyl sulphate (STS)
1 per cent and 3 per cent (Fibrovein™; STD Pharma-
ceutical Products, Hereford, UK). The injection of foam
was monitored by ultrasound imaging. After treatment, a
compression stocking was applied with the instruction to
wear it continuously for 3 days, followed by daytime use for
11 days. At 1-month follow-up, a duplex ultrasound exam-
ination was done and, if any reflux was observed, a second
treatment with foam was carried out. These patients were
seen again 4weeks after the second treatment, and the
need for a possible third treatment was checked by duplex
imaging.
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Excluded n = 365
 Did not meet inclusion criteria n = 258
 Refused to participate n = 72
 Other reason n = 35
Allocated to surgery n = 74
Received allocated intervention n = 65
Did not receive allocated intervention n = 9
 Met exclusion criteria n = 4
 Unhappy about randomization group n = 5
Allocated to UGFS n = 81
Received allocated intervention n = 76
Did not receive allocated intervention n = 5
 No particular reason n = 1
 Met exclusion criteria n = 4
Lost to follow-up n = 4
 Moved to another city n = 3
 No reason n = 1
Discontinued intervention n = 0
Lost to follow-up n = 4
 Moved to another city n = 2
 No particular reason n = 2
Discontinued intervention n = 0
Analysed n = 61
Excluded from analysis n = 0
Analysed n = 72
Excluded from analysis n = 0
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 Treated with surgery n = 5
Analysed n = 73
Excluded from analysis n = 0
Assessed for eligibility n = 598
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Fig. 1 CONSORT diagram for the trial. EVLA, endovenous laser ablation; UGFS, ultrasound-guided foam sclerotherapy
Assessments
The primary outcome measures were: 1-year occlusion
(or absence) rate of GSV on routine duplex imaging, and
changes in disease-specific quality of life according to the
Aberdeen Varicose Vein Severity Score (AVVSS)9. The
diameter of the GSV 20 cm below the groin was also
measured and compared with preoperative values. Sec-
ondary outcome measures were: perioperative pain mea-
sured using a visual analogue scale (VAS) from 0 (no
pain) to 10 (worst possible, unbearable, excruciating pain)
at the time of discharge and at 1week after the proce-
dure; duration of sick leave; and rate of complications
such as haematoma, pigmentation, thrombophlebitis and
paraesthesia.
Statistical analysis
Sample size calculations indicated that to detect a 20 per
cent difference in occluded or absent GSV between the
groups, with α= 0⋅05 and β= 0⋅8, 70 patients would be
needed in each group.
Data were analysed according to intention to treat. The
primary endpoint, occlusion or absence of GSV, was anal-
ysed in the overall study group and in three subgroups
according to the size of the GSV in the mid-thigh.
Continuous variables are reported as mean(s.d.) (range).
Baseline and follow-up variables were compared using the
paired-samples t test and repeated-measures test. Statistical
analysis was done using statistical software for Windows®
(SPSS® version 19.0; IBM, Armonk, New York, USA).
Results
A total of 598 consecutive patients were screened between
November 2007 andMay 2010. Of these, 233 patients (233
legs) fulfilled the inclusion criteria and were willing to par-
ticipate; they were randomized in the trial (Fig. 1). Nine-
teen randomized patients were excluded from the study
before treatment. The most common reason was that the
patient met an exclusion criterion that was not recognized
at the time of randomization. Thus, the final study popu-
lation comprised 214 patients: 65 in the surgery group, 73
in the EVLA group and 76 in the UGFS group. Owing
to the operating surgeon’s preference, five patients orig-
inally randomized to EVLA were treated with surgery
but, because the analysis was made according to inten-
tion to treat, these patients were analysed in EVLAgroup.
All 214 patients attended the 1-month follow-up, and
206 (96⋅3 per cent) the 1-year follow-up: 61 of 65 after
surgery, all 73 patients who had EVLA and 72 of 76 who
had UGFS.
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Table 1 Demographics and preoperative measurements
Surgery
(n=65)
EVLA
(n=73)
UGFS
(n=76)
Total
(n=214)
Age (years)* 47⋅3(11⋅3) (27–75) 47⋅0(13⋅4) (20–73) 48⋅3(12⋅7) (23–74) 47⋅6(12⋅4) (20–75)
Sex ratio (F :M) 55 : 10 55 : 18 58 : 18 168 : 46
BMI (kg/m2)* 25⋅1(3⋅7) (19–37) 25⋅2(3⋅6) (19–35) 25⋅8(4⋅6) (20–42) 25⋅4(4⋅0) (19–42)
Diameter of GSV (mm)
At SFJ 8⋅7(2⋅0) (5–14) 8⋅5(2⋅2) (5–15) 8⋅4(1⋅7) (5–13) 8⋅5(2⋅0) (5–15)
Below groin 6⋅6(1⋅3) (4–11) 6⋅8(1⋅2) (4–10) 6⋅7(1⋅2) (4–10) 6⋅7(1⋅2) (4–11)
Mean 6⋅2(1⋅1) (4–9) 6⋅3(1⋅1) (4–8) 6⋅7(1⋅1) (4–9) 6⋅2(1⋅1) (4–9)
Baseline CEAP class
C2 33 27 26 86
C3 26 36 37 99
C4 6 10 13 29
Baseline AVVSS* 30⋅2(6⋅3) (16–45) 32⋅4(6⋅7) (18–51) 31⋅7(7⋅6) (13–52) 31⋅5(6⋅9) (13–52)
Values are mean(s.d.) range. EVLA, endovenous laser ablation; UGFS, ultrasound-guided foam sclerotherapy; GSV, great saphenous vein; SFJ,
saphenofemoral junction; CEAP, Clinical Etiologic Anatomic Pathophysiologic; AVVSS, Aberdeen Varicose Vein Severity Score.
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Fig. 2 Patency of the great saphenous vein (GSV) at various diameters on duplex ultrasound imaging 1 year after a surgery,
b endovenous laser ablation (EVLA) or c ultrasound-guided foam sclerotherapy (UGFS)
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There were no significant differences in the basic demo-
graphics, CEAP clinical classification, AVVSS or GSV
dimensions at baseline between the study groups (Table 1).
Perioperative results
The mean(s.d.) duration of treatment was 95(19) (range
62–155) min in the surgery group and 83(17) (range
50–139) min in the EVLA group (P< 0⋅001). Twenty-six
patients (34 per cent) in the UGFS group received two
treatments; no patient required a third treatment. The scle-
rosants employed for the first treatment were: STS 3 per
cent (64 patients), STS 1 per cent (6), polidocanol 3 per
cent (4) and polidocanol 1 per cent (2). The mean volume
of foam used in the GSV was 4⋅7(1⋅6) (range 2⋅0–9⋅0) ml.
Some 33 per cent also had foam injected into varicose tribu-
taries: mean volume 4⋅6 (range 2⋅0–12⋅0) ml. In the second
treatment session, the mean volume of foam used in the
GSV was 3⋅8 (2⋅0–10⋅0) ml.
Primary outcome measures
At 1 year, the GSVwas completely occluded or absent in 59
(97 per cent) of 61 patients after surgery, 71 (97 per cent) of
73 after EVLA and 37 (51 per cent) of 72 after UGFS. The
GSV was partially occluded in two patients (3 per cent),
none (0 per cent) and 21 patients (29 per cent) in the respec-
tive groups. The difference between UGFS and the two
other treatments was significant (P< 0⋅001). No patient in
the surgery group and only two (3 per cent) in the EVLA
group had a patent GSV after 1 year, compared with 14 (19
per cent) in the UGFS group. Of the two patients with a
patentGSV in the EVLA group at 1 year, one had a tiny but
patent GSVwith no reflux and the other had asymptomatic
reflux in a very narrow GSV. On duplex imaging at 1 year,
reflux was seen in the below-knee GSV in 13, 16 and 33 per
cent of patients in the surgery, EVLA and UGFS groups
respectively (P= 0⋅008 for UGFS versus other two proce-
dures). Reflux in another unnamed thigh vein was present
in 8, 10 and 12 per cent respectively (P= 0⋅471 between
groups). When GSV patency rates were analysed accord-
ing to size of the GSV before treatment, there was a clear
correlation between larger diameter and GSV patency, but
only in the UGFS group (Fig. 2).
At baseline, there were no significant differences in
median AVVSS between the groups. At 1 year, median
AVVSS was significantly improved in all groups and there
were no significant differences between the groups (Fig. 3).
After the 1-year follow-up visit, 16 patients had addi-
tional treatment: four patients (7 per cent) in the surgery
group (UGFS for a thigh vein in 3 patients and ligation
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Fig. 3 Disease-specific quality of life, measured by Aberdeen
Varicose Vein Severity Score (AVVSS) at baseline and 1 year after
surgery, endovenous laser ablation (EVLA) or ultrasound-guided
foam sclerotherapy (UGFS). Values are means with 95 per cent
confidence intervals
of a perforating vein in 1); one patient (1 per cent) after
EVLA (foam sclerotherapy to a tributary at the ankle); and
11 patients (15 per cent) after UGFS (2 stripping of GSV,
5 EVLA of GSV and 4 repeat UGFS) (P= 0⋅009).
Secondary outcome measures
Pain after treatment was significantly reduced (lower VAS
score) after UGFS in comparison with the surgery and
EVLA groups, both at the time of discharge, and after
1week (Fig. 4).
The mean duration of sick leave was 12(6) (range 0–33)
days after surgery, 8(5) (range 0–29) days after EVLA and
1(3) (range 0–21) days after UGFS (P< 0⋅001 between
UGFS and the 2 other groups).
There were no major complications related to the proce-
dures. Three patients (4 per cent) in the EVLA group and
three (5 per cent) in the surgery group had a superficial
wound infection. All resolved with oral antibiotics; none of
the patients needed treatment in hospital.
At the 1-month follow-up, 62 per cent of patients in
the surgery group had a haematoma (defined as visible
localized aggregate of extravasated blood) in the operated
leg, compared with 42 per cent in the EVLA group and 20
per cent in the UGFS group (P= 0⋅001 between groups).
© 2016 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2016; 103: 1438–1444
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Fig. 4 Pain measured on a visual analogue scale (VAS; 1, none; 10, worst possible) a at the time of hospital discharge and b 1 week after
surgery, endovenous laser ablation (EVLA) or ultrasound-guided foam sclerotherapy (UGFS)
Skin pigmentation was more common after UGFS (67
per cent) than after surgery and EVLA (5 and 4 per cent
respectively; P< 0⋅001 for UGFS versus other 2 groups).
Paraesthesia was rare in all groups (2, 3 and 1 per cent
respectively). Palpable lumps in the veins under the skin
were present at 1 month in 54 per cent of patients after
surgery, 47 per cent after EVLA and 91 per cent after
UGFS (P< 0⋅001 for UGFS versus other two groups).
Discussion
The present prospective randomized trial compared three
interventions for unilateral primary great saphenous vari-
cose veins. Reflux in the GSV was extremely rare at 1 year
after surgical stripping or EVLA; however, after UGFS,
reflux was seen in half of the patients, and the GSV was
patent and refluxing in one of five. Despite these differ-
ences, disease-specific quality of life was significantly better
in all groups at 1 year compared with preoperative values,
with no significant differences between the interventions.
Although recurrent/residual GSV reflux was seen in
every other patient treated with UGFS, quality of life
remained better than before surgery. One-year follow-up
may be too early to show the consequences of recurrent
reflux. The findings were similar in a multicentre study7
from the Netherlands that included 400 patients.
The largest trial comparing surgery, EVLA and UGFS
in the treatment of GSV reflux included 798 patients, of
whom 84 per cent completed 6months of follow-up9. In
this series the complete success rate after 6months was 78,
82 and 43 per cent respectively in the surgery, EVLA and
UGFS groups. Similar to the present study, disease-specific
quality of life was significantly better in all three groups
after 6months than before intervention, but worse after
UGFS. The same trend was seen in other studies5–7,10.
The present study also examined the effect of GSV
diameter on outcome. The occlusion rate after UGFS was
clearly associated with GSV diameter: less than 40 per
cent in GSVs of 9mm or larger in mid-thigh diameter,
compared with 75 per cent in GSVs of less than 6mm. This
suggests that UGFS should not be recommended for veins
larger than 6mm in diameter.
There are some short-term advantages from UGFS.
In all three groups, patients reported increased pain
after 1week compared with immediately after treat-
ment; the proportion of patients with no or minimal
pain decreased during the first week. The majority
of patients who had UGFS had no or minimal pain
at 1week. These findings contrast with those of Ras-
mussen and colleagues6, who reported that patients who
had surgery or EVLA had the worst pain immediately
after the procedure, which improved steadily over the
first week. Some of the variation may be explained by
the differences in the timing of the first measurement.
In the present study, patients reported the VAS score
immediately before discharge, when they may have had
some remaining effects of perioperative analgesia. In the
Danish study, the first measurement was completed on the
first postoperative day.
Similarly, recovery from the intervention was fastest
in patients who underwent UGFS. Recovery to daily
work was longest after surgery; duration of sick leave was
also greatest in the surgery group. These results accord
with other studies2,3, which reported sick leave of 1week
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after EVLA and 2weeks after surgery. Rasmussen and
colleagues6 reported shorter sick leave of 7⋅6 days after
surgery, possibly owing to the use of tumescent anaesthesia
in surgical procedures.
The strength of the present study is that it was random-
ized, with excellent follow-up, 96⋅3 per cent at 1 year. The
main weakness is the relatively short follow-up so far. The
long-term consequence of the high reflux rate after UGFS
remains unclear. Another issue is that the foam used was
more concentrated (air to sclerosant ratio 2 : 1) than in
other studies. The impact of this is unknown as there are
no randomized trials regarding the optimal foam recipe.
Patients with great saphenous varicose veins should
understand that, although UGFS has some short-term
advantages in recovery, and equivalent quality of life after
1 year, longer follow-up of the present patients may reveal
that the higher rate of recurrent/residual GSV reflux at
1 year increases the long-term risk of recurrent varicose
veins.
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